Intellia Therapeutics, Inc. (NTLA) Stock Forecast
NTLA analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 3.65 / 5 from 20 analysts
- Price target
- $23.11 average of analyst targets
- Upside to target
- +102.4% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-0.82
- 52-week range
- $8.04 – $27.98
NTLA analyst ratings
20 analystsNumber of analysts at each rating.
NTLA price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
NTLA earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.79 | −$0.89 | −$0.71 | −$0.92 | +14.6% | 16 |
| Current fiscal year (2026) | −$3.14 | −$3.41 | −$2.83 | −$3.81 | +17.5% | 17 |
| Next fiscal year (2027) | −$2.56 | −$3.62 | $0.97 | −$3.14 | +18.4% | 17 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
NTLA revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $9.8M | $0 | $15.0M | −29.1% | 15 |
| Current fiscal year (2026) | $51.9M | $22.7M | $100.0M | −23.3% | 17 |
| Next fiscal year (2027) | $126.3M | $8.8M | $685.6M | +143.4% | 17 |
NTLA EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
NTLA revenue: reported and forecast
NTLA EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.78 | −$0.79 | −$0.79 | −$0.79 | −$0.79 | +0.7% | 2 up · 0 down |
| Current fiscal year (2026) | −$3.14 | −$3.15 | −$3.16 | −$3.15 | −$3.14 | +0.1% | 2 up · 2 down |
| Next fiscal year (2027) | −$1.76 | −$2.60 | −$2.60 | −$2.57 | −$2.56 | +45.9% | 3 up · 2 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
NTLA earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; NTLA beat in 10 of 12.
What analysts expect from NTLA
20 analysts cover Intellia Therapeutics; their consensus rating is buy (3.65 on a 1–5 scale, where 5 is a strong buy). The average price target is $23.11, 102.4% above the latest close of $11.42. Analysts expect earnings of −$3.14 per share for 2026, +17.5% from a year earlier. For 2027 the average estimate is −$2.56 per share on revenue of $126.3 million. Intellia Therapeutics beat the EPS estimate in 10 of the last 12 quarters.
Related: NTLA income statement, NTLA key metrics, NTLA chart. See the NTLA stock overview for the latest quote and news.
NTLA forecast FAQ
What is Intellia Therapeutics's price target?
The average analyst price target for Intellia Therapeutics is $23.11, 102.4% above the latest close of $11.42.
Is Intellia Therapeutics a buy, hold or sell?
Of 20 analysts covering Intellia Therapeutics, 9 rate it a strong buy, 1 a buy, 6 a hold, 2 a sell and 2 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Intellia Therapeutics's EPS forecast?
Analysts forecast −$3.14 per share for 2026 (range −$3.41 to −$2.83); for 2027 the estimate is −$2.56.
What is Intellia Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $51.9 million, growth of −23.3%; for 2027 it is $126.3 million.
When does Intellia Therapeutics report earnings?
Intellia Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 before the market opens; the EPS estimate is $-0.82.
Does Intellia Therapeutics usually beat earnings estimates?
Intellia Therapeutics reported EPS at or above the analyst estimate in 10 of the last 12 quarters.